Host antitumor immune response stimulation

"Host antitumor immune response stimulation" is a collective term describing any therapeutic strategy or biological process that enhances the host’s immune response against tumors. This typically involves activating innate and adaptive immune cells (such as dendritic cells, T cells, and natural killer cells) within the tumor microenvironment, often through signaling pathways like cGAS-STING, TLRs, and RIG-I/MDA-5. Exogenous agents (e.g., STING agonists, TLR ligands, checkpoint inhibitors) and chemotherapy can drive these responses by promoting antigen presentation, cytokine release (especially type I interferons), and restoring immune cell infiltration and function. While stimulation of host antitumor immunity holds promise for effective cancer therapy, it is not a singular molecular entity and can involve complex regulatory feedback, possible adverse immune effects, and risk for immune-mediated tissue damage[1][2][3][4].

Other names

Host anti-tumor immunity stimulationHost antitumor immunity activationAntitumor immune responseHost immune response to tumorImmune activation against tumor

Activation of innate immune pathways (cGAS-STING, TLR, RIG-I/MDA-5, etc.) in dendritic cells and other antigen-presenting cells, leading to type I interferon and cytokine production and enhanced presentation of tumor antigens to T cells Release of danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (MAMPs) that promote immune cell recruitment and activation Blockade of immune checkpoints to prevent T cell exhaustion and suppression